Keros Therapeutics Stock Annual Yield

KROS Stock

USD 57.74 0.81 1.38%

Keros Therapeutics fundamentals help investors to digest information that contributes to Keros Therapeutics' financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Keros Therapeutics Company Annual Yield Analysis

Keros Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

Keros Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for Keros Therapeutics is extremely important. It helps to project a fair market value of Keros Stock properly, considering its historical fundamentals such as Annual Yield. Since Keros Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Keros Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Keros Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	1.0	0.51	-0.98	-0.85	0.92	0.85	0.85	0.95	0.61	1.0	1.0	-0.83	1.0	0.86	0.88	0.7	0.29	-0.48
Total Stockholder Equity	1.0		1.0	0.47	-0.98	-0.83	0.91	0.86	0.86	0.95	0.57	1.0	1.0	-0.84	1.0	0.88	0.88	0.68	0.31	-0.47
Net Tangible Assets	1.0	1.0		0.43	-0.97	-0.79	0.9	0.86	0.86	0.93	0.56	1.0	1.0	-0.83	1.0	0.88	0.86	0.66	0.33	-0.4
Current Deferred Revenue	0.51	0.47	0.43		-0.55	-0.8	0.47	0.16	0.16	0.65	0.87	0.45	0.49	-0.19	0.47	0.24	0.38	0.51	-0.18	-0.73
Net Debt	-0.98	-0.98	-0.97	-0.55		0.88	-0.89	-0.82	-0.82	-0.98	-0.55	-0.98	-0.98	0.84	-0.98	-0.85	-0.87	-0.67	-0.26	0.61
Retained Earnings	-0.85	-0.83	-0.79	-0.8	0.88		-0.88	-0.7	-0.7	-0.95	-0.75	-0.83	-0.84	0.73	-0.83	-0.68	-0.85	-0.8	-0.09	0.82
Accounts Payable	0.92	0.91	0.9	0.47	-0.89	-0.88		0.92	0.92	0.91	0.61	0.92	0.91	-0.89	0.91	0.86	0.97	0.82	0.35	-0.55
Long Term Debt	0.85	0.86	0.86	0.16	-0.82	-0.7	0.92		1.0	0.79	0.34	0.88	0.85	-0.97	0.86	0.83	0.95	0.79	0.31	-0.34
Long Term Debt Total	0.85	0.86	0.86	0.16	-0.82	-0.7	0.92	1.0		0.79	0.34	0.88	0.85	-0.97	0.86	0.83	0.95	0.79	0.31	-0.34
Capital Surpluse	0.95	0.95	0.93	0.65	-0.98	-0.95	0.91	0.79	0.79		0.63	0.95	0.95	-0.83	0.95	0.83	0.88	0.72	0.23	-0.69
Total Liab	0.61	0.57	0.56	0.87	-0.55	-0.75	0.61	0.34	0.34	0.63		0.56	0.59	-0.26	0.57	0.3	0.51	0.67	-0.13	-0.46
Net Invested Capital	1.0	1.0	1.0	0.45	-0.98	-0.83	0.92	0.88	0.88	0.95	0.56		1.0	-0.86	1.0	0.88	0.89	0.69	0.32	-0.46
Total Current Assets	1.0	1.0	1.0	0.49	-0.98	-0.84	0.91	0.85	0.85	0.95	0.59	1.0		-0.83	1.0	0.87	0.87	0.68	0.31	-0.47
Capital Stock	-0.83	-0.84	-0.83	-0.19	0.84	0.73	-0.89	-0.97	-0.97	-0.83	-0.26	-0.86	-0.83		-0.84	-0.84	-0.93	-0.75	-0.32	0.45
Net Working Capital	1.0	1.0	1.0	0.47	-0.98	-0.83	0.91	0.86	0.86	0.95	0.57	1.0	1.0	-0.84		0.88	0.87	0.67	0.32	-0.46
Short Term Debt	0.86	0.88	0.88	0.24	-0.85	-0.68	0.86	0.83	0.83	0.83	0.3	0.88	0.87	-0.84	0.88		0.79	0.44	0.71	-0.37
Common Stock	0.88	0.88	0.86	0.38	-0.87	-0.85	0.97	0.95	0.95	0.88	0.51	0.89	0.87	-0.93	0.87	0.79		0.87	0.22	-0.58
Property Plant Equipment	0.7	0.68	0.66	0.51	-0.67	-0.8	0.82	0.79	0.79	0.72	0.67	0.69	0.68	-0.75	0.67	0.44	0.87		-0.2	-0.52
Net Receivables	0.29	0.31	0.33	-0.18	-0.26	-0.09	0.35	0.31	0.31	0.23	-0.13	0.32	0.31	-0.32	0.32	0.71	0.22	-0.2		0.08
Deferred Long Term Liab	-0.48	-0.47	-0.4	-0.73	0.61	0.82	-0.55	-0.34	-0.34	-0.69	-0.46	-0.46	-0.47	0.45	-0.46	-0.37	-0.58	-0.52	0.08

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict Keros Therapeutics

In accordance with the recently published financial statements, Keros Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Keros Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		172.6M	828.8M	1.1B	946.3M	854.1M	545.9M

Keros Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Keros Fundamentals

	Return On Equity	-0.44
	Return On Asset	-0.28
	Operating Margin	(151.18) %
	Current Valuation	1.86 B
	Shares Outstanding	40.51 M
	Shares Owned By Insiders	5.40 %
	Shares Owned By Institutions	94.60 %
	Number Of Shares Shorted	2.22 M
	Price To Book	4.45 X
	Price To Sales	3,643 X
	Revenue	151 K
	Gross Profit	(87.27 M)
	EBITDA	(152.18 M)
	Net Income	(152.99 M)
	Cash And Equivalents	215.62 M
	Cash Per Share	8.37 X
	Total Debt	14.44 M
	Debt To Equity	0 %
	Current Ratio	14.39 X
	Book Value Per Share	13.57 X
	Cash Flow From Operations	(124.51 M)
	Short Ratio	5.73 X
	Earnings Per Share	(5.22) X
	Target Price	90.69
	Number Of Employees	160
	Beta	1.24
	Market Capitalization	2.37 B
	Total Asset	370.02 M
	Retained Earnings	(381.43 M)
	Working Capital	322.92 M
	Current Asset	11.95 M
	Current Liabilities	5.72 M
	Net Asset	370.02 M

About Keros Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC